Subscribe To
Day one announces new firefly-1 data for tovorafenib (day101) and initiation of rolling nda submission to fda for relapsed or progressive pediatric low-grade glioma
Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to ...
June 4, 2023, 4:45 pm
Bristol myers squibb to present late-breaking data for breyanzi (lisocabtagene maraleucel) in relapsed or refractory follicular lymphoma and mantle cell lymphoma at 2023 international conference on ma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #17ICML--BMS to Present Late-Breaking Data for Breyanzi in relapsed<...
May 30, 2023, 9:24 am
Bristol myers squibb to present late-breaking data for breyanzi (lisocabtagene maraleucel) in relapsed or refractory follicular lymphoma and mantle cell lymphoma at 2023 international conference on ma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #17ICML--BMS to Present Late-Breaking Data for Breyanzi in relapsed<...
May 30, 2023, 9:24 am
Abbvie (abbv) gets fda nod for lymphoma drug epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large ...
May 22, 2023, 1:35 pm
Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-...
May 21, 2023, 8:05 pm
Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-...
May 21, 2023, 8:05 pm
Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-...
May 21, 2023, 8:05 pm
Nexcella announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinical tria
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-...
May 21, 2023, 8:05 pm
Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-...
May 21, 2023, 8:00 pm
Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-...
May 21, 2023, 8:00 pm
Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-...
May 21, 2023, 8:00 pm
Immix biopharma announces positive nxc-201 clinical results at asgct: 100% overall response rate in darzalex-relapsed/refractory al amyloidosis with zero icans in ongoing nexicart-1 phase 1b/2a clinic
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-...
May 21, 2023, 8:00 pm
Gracell biotechnologies to present clinical data on bcma/cd19 dual-targeting fastcar-t gc012f in rrmm and b-nhl and donor-derived car-t gc007g in b-all at eha2023 congress
First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety...
May 11, 2023, 5:28 pm
Gracell biotechnologies to present updated clinical data on bcma/cd19 dual-targeting fastcar-t gc012f at 2023 asco annual meeting
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: G...
April 26, 2023, 10:15 am
Bristol myers' (bmy) breyanzi gets positive chmp opinion
Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed ...
April 3, 2023, 1:41 pm
Karyopharm therapeutics: expanding beyond the crowded multiple myeloma market
Shares are down 50% over the past year as fierce competition in the multiple myeloma space negatively impacts Xpovio's growth prospects. However, ther...
March 20, 2023, 4:43 am
Glycomimetics: stock price drop brings great speculative trade opportunity
Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the tr...
March 8, 2023, 11:20 pm
Day one reports fourth quarter and full year 2022 financial results and corporate progress
First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with...
March 6, 2023, 9:30 pm
Nexcella, inc. presents 42-patient interim data, with 90% overall response rate in relapsed or refractory multiple myeloma at nxc-201 therapeutic dose from its phase 1 expansion trial at the 5th europ
The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated ...
February 9, 2023, 1:05 pm
Caribou: potential to improve response duration with higher dose level
Proof of concept established from the phase 1 ANTLER study in using Dose level 1 of CB-010 for the treatment of patients with ...
January 24, 2023, 7:12 am